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Abstract:  The  adrenergic  receptors  are  among  the  best  characterized  G  protein-coupled  receptors  (GPCRs)  and 
knowledge on this receptor family has provided several important paradigms about GPCR function and regulation. One of 
the most recent paradigms initially supported by studies on adrenergic receptors is that both βarrestins and G protein-
coupled receptors themselves can act as scaffolds binding a variety of proteins and this can result in growing complexity 
of the receptor-mediated cellular effects. In this review we will briefly summarize the main features of βarrestin binding 
to the adrenergic receptor subtypes and we will review more in detail the main proteins found to selectively interact with 
distinct AR subtype. At the end, we will review the main findings on oligomerization of the AR subtypes. 
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INTRODUCTION 
  The  adrenergic  receptors  (AR)  mediate  the  functional 
effects  of  catecholamines,  like  epinephrine  and  norepine-
phrine, by coupling to different signaling pathways modula-
ted by G proteins. The adrenergic receptor family includes 
nine different gene products,  three β (β1, β2, β3), three α1 
(α1a , α1b and α1d) and three α2 (α2A, α2B and α2C) receptor 
subtypes. 
  The adrenergic receptors, and in particular the β2AR, are 
among  the  best  characterized  G  protein-coupled  receptors 
(GPCRs)  and  knowledge  on  this  receptor  family  has 
provided several important paradigms about GPCR function 
and regulation. 
  One of the most recent paradigms initially supported by 
studies  on  adrenergic  receptors  is  that  G  protein-coupled 
receptors can act as scaffolds binding a variety of proteins 
and this can promote multiple signaling events which results 
in  growing  complexity  of  the  receptor-mediated  cellular 
effects (reviewed in ref. [1]).  
  In the late 1980s, the first protein found to interact with 
the β2AR, beyond G proteins, was βARK1 (βAR kinase 1) 
[2], discovered as the first member of the G protein-coupled 
receptor kinase family (GRK) [3]. The ability of GRK2 and 
3 to selectively interact with the agonist-bound form of the 
β2AR  was  a  crucial  observation  to  identify  their  role  in 
homologous desensitization.  
  Soon after the discovery of GRKs,  it became  apparent 
that β2AR desensitization required also the interaction of an 
arrestin protein with the phoshorylated receptor [2, 4]. This 
interaction  resulted  in  both  receptor-G  protein  uncoupling 
and receptor endocytosis into clathrin-coated pits [5].  
  In the last ten years, an important function of βarrestins 
has  come  to  light  as  scaffolds  for  a  growing  number  of  
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signaling  proteins  thus  coordinating  complex  signal  trans-
duction events [6]. In particular, it  is well established that 
βarrestins  are  scaffolds  for  components  of  the  mitogen 
activated  protein  kinase  (MAPK)  cascade  thus  mediating 
MAPK activation induced by various GPCRs. 
  This  seminal  work  encouraged  the  search  for  novel 
protein-protein interactions at several GPCRs with the aim of 
identifying previously unappreciated signaling mechanisms 
that might represent new  targets of pharmacological inter-
vention.  A  number  of  approaches  have  been  followed  to 
identify  novel  proteins  interacting  with  the  receptors, 
including yeast two-hybrid screen using cytosolic portions of 
the receptors  as bait, pull-down or in  vitro overlay assays 
using purified proteins, co-immunoprecipitation of receptor-
protein complexes from recombinant or native cells, FRET 
(fluorescence  resonance  energy  transfer)  or  BRET  (biolu-
minescence resonance energy transfer) technology in cells. 
These  studies  resulted  in  the  identification  of  a  variety  of 
proteins interacting with the adrenergic receptors, several of 
them in a receptor subtype selective pattern. A major chal-
lenge faced by these studies has been to identify the func-
tional  implications  of  these  interactions.  Some  interacting 
proteins  have  been  found  to  either  promote  or  impair 
receptor-mediated signaling whereas others are involved in 
receptor trafficking or endocytosis.  
  Among the protein-protein interactions found to regulate 
GPCR  function,  receptor  oligomerization  has  been  exten-
sively  investigated  in  recent  years  [7].  Both  homo-  and 
hetero-oligomerization  have  been  reported  for  different 
adrenergic  receptor  subtypes  using  different  experimental 
approaches. This phenomenon seems to have implications in 
different aspects of receptor function, including its pharma-
cological profile, signaling, trafficking or endocytosis. 
  The  canonical  interactions  of  the  adrenergic  receptors 
with G proteins, GRKs and βarrestins have been extensively 
studied and exhaustively reviewed elsewhere [8, 9]. In this 
review  we  will  briefly  summarize  the  main  features  of 
βarrestin binding to the adrenergic receptor subtypes and we 
will review, more in detail, a number of proteins found to 
selectively interact with distinct AR subtype. At the end, we 
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subtypes.  Considering the large number of studies on pro-
tein-protein  interactions  at  GPCRs,  our  review  might  not 
systematically include all published data.  
  The direct  interaction of GPCRs with selected partners 
has  recently  emerged  as  a  new  mechanism  of  receptor 
signaling and regulation. Since these mechanisms might be 
specific for distinct receptors or cell types, the study of these 
interactions  has  interesting  implications  in  pharmacology 
and drug development.  
βARRESTIN  INTERACTION  WITH  THE  AR 
SUBTYPES 
  The well established crucial role played by βarrestin1 and 
2  in  coordinating  a  variety  of  signaling  networks  might 
imply that  these proteins can form macromolecular comp-
lexes with virtually any GPCR.  
  The  interaction  of  βarrestins  with  the  β2AR  has  been 
extensively  characterized  both  at  functional  and  molecular 
level using different approaches including in vitro binding of 
purified proteins, co-immunoprecipitation, BRET or FRET, 
βarrestin  translocation  as  well  as  confocal  microscopy  to 
assess  colocalization  of  the  proteins  [6,  8,  9].  The  β2AR 
displays a pattern of interaction with βarrestins defined as 
"Class  A"  characterized  by  greater  affinity  for  βarrestin  2 
than 1 and a short-lived receptor/βarrestin complex leading 
to rapid receptor recycling after endocytosis. The interaction 
with  βarrestins  is  important  in  mediating  β2AR-induced 
activation of ERK1/2 (see references in [6]). 
  In contrast to the significant amount of data on the β2AR, 
much less is known about the interaction of βarrestins with 
other  AR  subtypes.  The  interaction  of  the  β1AR  with 
βarrestin is much weaker than that displayed by the β2AR 
subtype and this seems to correlate with the resistance of the 
β1AR  to  undergo  agonist-induced  endocytosis  [10]. 
However, the β1AR can transactivate the epithelial growth 
factor (EGF) receptor  in  a βarrestin-dependent  mechanism 
and this effect might have implications in cardioprotection 
[11].  This  is  suggested  by  a  recent  study  reporting  that 
recruitment of βarrestin to the C-tail of the β1AR is required 
for maintaining the β1AR/EGF receptor complex. 
  Also the β3AR does not seem to interact with βarrestins 
as  suggested  by  two  lines  of  evidence.  First,  the  β3AR  is 
resistant  to  agonist-induced  endocytosis  [12].  Second,  the 
ability of the β3AR to activate MAPK is independent from 
βarrestin  binding  since  its  activation  does  not  result  in 
βarrestin recruitment to the plasma membrane [13]. 
  The interaction of βarrestin with the α2AR was initially 
investigated measuring the effect of overexpressed βarrestin 
on  receptor  endocytosis  [14].  Overxpression  of  βarrestin 
significantly  increased  the  endocytosis  of  the  α2B  and 
α2CAR,  but  had  no  effect  on  the  α2AAR  suggesting  poor 
interaction of this receptor subtype with βarrestin. The lack 
of βarrestin interaction with the α2AAR was confirmed by in 
vitro studies measuring the binding of purified βarrestin to 
peptides derived from the 3i loop of the three α2AR subtypes 
[15].  
  The  interaction  of  the  α1a  and  α1bAR  subtypes  with 
βarrestin has been investigated by a recent study using dif-
ferent  approaches  including  co-immunoprecipitation,  endo-
cytosis and confocal microscopy [16]. Whereas the α1bAR 
displayed robust agonist-induced endocytosis, the α1aAR did 
not.  The  results  from  both  co-immunoprecipitation  experi-
ments and βarrestin translocation  assays  indicated  that  the 
agonist-induced interaction of the α1aAR with βarrestin was 
much  weaker  than  that  of  the  α1bAR.  The  interaction  of 
βarrestin with the α1dAR has not been directly explored so 
far. 
  Altogether  these  findings  indicate  that  the  interaction 
pattern of βarrestin with distinct AR subtypes is divergent 
and  correlates  with  differences  in  the  internalization 
properties of the receptors. Overall, despite the large number 
of studies on the β2AR, a lot remains to be explored con-
cerning the implications of βarrestin in adrenergic receptor 
function and regulation. 
PROTEINS INTERACTING AT THE β1AR  
  The  first  cytoplasmic  proteins  found  to  interact  select-
ively  with  the  β1AR  subtype  were  endophilins  1/2/3,  also 
called  SH3p4/p8/p13  [17].  This  SH3  domain-containing 
protein family bound the proline-rich third intracellular (i3) 
loop of the β1AR in both pull-down assays  and yeast two 
hybrid screens. The primary effect of this interaction was to 
promote agonist-induced internalization of the receptor and 
to  modestly  decrease  its  coupling  to  Gs.  Intriguingly,  a 
similar proline-rich sequence is found in the i3 loop of the β3 
or α2AAR, but these receptors do not bind endophilins. The 
mechanism  through  which  endophilin  might  regulate 
receptor  coupling  and  internalization  is  not  known,  but  it 
could include steric hindrance or allosteric modulation of G 
protein and arrestin binding. 
  A second class of proteins selectively interacting with the 
β1AR  are  proteins  containing  the  PDZ  (PSD-95/Discs-
large/ZO-1 homology) domain which recognizes the extreme 
C-terminus of the target protein. The β1AR possesses a type I 
PDZ binding sequence, E-S-K-V, at the end of its C-tail and 
it has been shown to bind the postsynaptic protein PSD-95 
[18]. This protein is abundant in brain where it co-localizes 
with the β1AR in postsynaptic densities. This interaction was 
found  in  a  yeast  two-hybrid  screening  using  the  β1AR  C-
terminus as bait and it markedly attenuated β1 internaliza-
tion, while having no impact on the receptor desensitization 
or signaling to adenylate cyclase. Association with PSD-95 
could  also  facilitate  the  linkage  of  the  β1  to  NMDA 
glutamate  receptors,  known  to  be  regulated  by  adrenergic 
signaling  in  the  brain,  and,  more  in  general,  to  facilitate 
targeting  of  the  β1AR  subtype  at  synapses.  Other  studies 
demonstrated that the interaction with PSD-95 is negatively 
regulated by agonist treatment, through phosphorylation of 
the receptor by GRK5, thus allowing receptor internalization 
[19].  
  A  second  PDZ  domain  containing  protein  interacting 
with  the  β1AR  is  membrane-associated  guanylate  kinase 
inverted-2 (MAGI-2),  a multidomain scaffold protein, also 
known  as  S-SCAM  (synaptic  scaffolding  molecule).  The 
first PDZ domain of MAGI-2 binds with high affinity to the 
β1AR  C-tail,  as  demonstrated  by  overlay  and  pull-down 
techniques  [20].  The  β1AR/MAGI-2  interaction  occurred 
constitutively in cells, but it was further enhanced by isopro-
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of the receptor, an effect opposite to the one observed for 
PSD-95,  another  PDZ-domain  protein  [18].  MAGI-2  also 
promoted β1AR association to βcatenin, a known MAGI-2 
partner.  
  A third PDZ domain containing protein binding the β1AR 
is  GIPC  (Gα-interacting  protein-interacting  protein,  C  ter-
minus)  [21].  This  interaction  decreased  ERK1/2  activity 
stimulated  by  the  β1AR,  through  a  Gi-dependent  process, 
with no observable effects on the Gs-mediated cAMP accu-
mulation or on receptor internalization. One last example of 
a PDZ domain-mediated interaction with the β1AR is CAL 
(Cystic  Fibrosis  Transmembrane  Conductance  Regulator-
Associated  Ligand),  found  by  pull-down  techniques  to 
interact with the ESKV sequence of the β1AR [22]. Over-
expression of CAL, a protein localized in the Golgi appara-
tus,  reduced  surface  expression  of  the  receptor,  a  process 
competitively reversed by PSD-95. 
  GPCRs  can  indirectly  activate  Ras  through  the  Gβγ 
subunits of the G protein that can recruit c-Src, Grb-Sos and 
PI3 kinase. The β1AR was the first GPCR for which a direct 
interaction  with  a  Ras-GEF  (GTP  exchange  factor), 
CNrasGEF, had been described [23]. CNrasGEF bound the 
ESKV sequence of the β1AR through its PDZ domain and 
mediated isoproterenol-induced Ras activation.  
  The importance of the PDZ binding sequence in the C-
tail  of  the  β1AR  was  highlighted  by  findings  obtained 
expressing the receptor in mouse cardiac myocytes [24]. In 
these cells, stimulation of the β1AR increases the contraction 
rate, whereas the β2AR has a biphasic effect with an initial 
increase  followed  by  a  decrease  mediated  by  receptor 
coupling  to  Gi.  In  addition,  whereas  the  β2AR  undergoes 
endocytosis, the β1AR does not. Interestingly, the mutation 
of  the  PDZ  binding  sequence  of  the  β1AR  enabled  both 
receptor  internalization  and  coupling  to  Gi  thus  providing 
evidence  that  differences  in  the  interaction  with  PDZ 
containing proteins might dictate  the distinct physiological 
effects induced by the two βAR subtypes.  
  Each of the four PDZ domain containing proteins above 
described,  although  binding  to  the  same  sequence  of  the 
β1AR, exerted different effects both on receptor trafficking 
and signaling. It is noteworthy that these four proteins do not 
share  the  same  tissue  distribution,  PSD-95  and  MAGI-2 
being almost exclusively found in the brain, whereas GIPC 
and CNasGEF being predominantly expressed in the heart. A 
recent  proteomic  screen  aimed  at  providing  an  exhaustive 
view of PDZ-mediated interactions at the β1AR, confirmed 
the association with PSD-95, MAGI-2, GIPC and CAL, and 
identified two novel ones, SAP97 and MAGI-3 [25]. MAGI-
3  co-expression  profoundly  impaired  β1AR-mediated 
ERK1/2 activation.  
  To  assess  the  GPCR  selectivity  of  these  interacting 
proteins a recent study used a library of 59 GPCR C-tails, 
among which those of the β1 and β2AR, in a pull-down assay 
[26].  This  approach  identified  the  lysosomal  targeting 
protein  GASP1  (G  protein-coupled  receptor-Associated 
Protein) as a potential interacting partner of the β1AR, but 
this  finding  was  not  explored  further.  GASP1  had  been 
previously  identified  in  a  yeast  two-hybrid  screen  as  a 
protein interacting with the  C-tail of the δ opioid receptor 
and shown to interfere with the post-endocytic sorting of the 
receptor. It was later discovered that GASP1 is member of a 
family of ten proteins displaying some sequence similarities 
whose  functional  implications  are  still  largely  unknown 
(reviewed in [27]). Whereas GASP1 can interact with several 
GPCRs  other  proteins  of  this  family  have  been  shown  to 
modulate  transcription.  Considering  these  two  important 
features, the GASP proteins might represent a promising area 
of investigation in the GPCR field.  
  Another protein recently shown to interact with the β1AR 
and influence it’s trafficking is golgin-160 which is a ubiqui-
tously expressed Golgi membrane protein [28]. Golgin-160, 
whose function in Golgi structure is unknown, can interact 
with the third intracellular loop of the β1AR and its depletion 
in cells leads to a significantly reduced cell surface expres-
sion of the receptor.  
  An interesting interaction was recently found between the 
β1AR and the adaptor protein 14-3-3epsilon both in recom-
binant cells and heart [29]. The receptor/14-3-3 complex can 
compete  with  the  interaction  occurring  between  14-3-
3epsilon and the voltage-gated potassium channel, Kv11.1, 
and this might represent a mechanism involved in adrenergic 
regulation of cardiac repolarization. Whereas the wild type 
β1AR inhibits potassium current, a receptor mutant lacking 
its  interaction  with  14-3-3  can  activate  it.  This  is  a  fasci-
nating finding highlighting the role of multiple protein inter-
actions in fine tuning of the physiological effects mediated 
by the adrenergic receptors on cardiac rhythms.  
  Another  finding  highlighting  the  potential  functional 
impact  of  different  signaling  complexes  in  heart  cells 
concerns the interaction of the β1 and β2AR subtypes with 
phosphodiesterases (PDE) [30]. Whereas the β2AR forms a 
complex with βarrestin and the PDE4D5 isoform, the β1AR 
can  directly  interact  with  the  PDE4D8  isoform  and  the 
agonist can dissociate this complex. Both the receptor and 
PDE4 are regulated in a complex manner by the cAMP/PKA 
cascade and binding of PDE4D to the β1AR might allow for 
the control of cAMP levels in proximity of the receptor. 
PROTEINS INTERACTING AT THE β2AR  
  PDZ  domain-mediated  interactions  are  also  known  to 
occur at the C-tail of the β2AR, which includes the type I 
PDZ-binding C-terminal sequence D-S-L-L. The first protein 
found to interact specifically with this sequence of the β2AR, 
but  not  with  β1AR,  was  NHERF1  (Na+/H+  Exchanger 
Regulatory  Factor  1),  also  named  EBP50  (ERM-  Binding 
Protein 50) [31]. This protein contains two PDZ domains and 
regulates  the  activity  of  the  Na
+/H
+  exchanger  type  3 
(NHE3).  In  addition,  NHERF  factors  represent  a  well 
established  link  between  ERM  (Ezrin-Radixin-Moesin) 
proteins and specific polytopic membrane proteins [32]. The 
β2AR/NHERF interaction might play a role in the receptor-
mediated regulation of cellular pH. Typically, an increase of 
intracellular cAMP levels inhibits NHE3 activity (via PKA-
mediated phosphorylation of NHERF), but the stimulation of 
the β2AR potentiates it. This is probably due to the fact that 
binding  of  the  β2AR  to  NHERF  relieves  the  NHERF-
mediated inhibition of NHE3.  
  NHERF can also be a link between the β2AR and other 
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derived  growth  factor  (PDGF)  receptor  [33]  and  cystic 
fibrosis transmembrane conductance regulator (CFTR) [34]. 
Whereas  PDGF  receptor-mediated  signaling  is  potentiated 
by its interaction with NHERF, the formation of the β2AR/ 
NHERF complex might regulate PDGF receptor function. A 
macromolecular complex composed of the β2AR, CFTR and 
NHERF was shown to form in human airway epithelia and 
this  complex  might  represent  an  important  mechanism 
underlying the β2AR-stimulated increase of CFTR activity. 
  In addition to mediating  these functional  effects of  the 
β2AR, the  interaction with NHERF seems  to play a direct 
role in receptor trafficking. The β2AR is a member of class A 
GPCRs,  being  characterized  by  rapid  agonist-induced 
endocytosis and recycling back to the plasma membrane. It 
was demonstrated that disruption of either NHERF binding 
to  the  β2AR  or  NHERF  binding  to  the  actin  cytoskeleton 
(mediated  by  NHERF/ERM  interaction)  caused  missorting 
of  endocytosed  β2AR  to  the  degradation  pathway  and 
prevented its recycling [35]. Actin depolymerization had a 
similar effect, implying that anchoring of the receptor to the 
actin  cytoskeleton  through  NHERF  and  ERM  proteins 
ensures  its  proper  trafficking  following  endocytosis.  A 
similar role for NHERF in directing the recycling of several 
other GPCRs was subsequently documented [32].  
  Another protein that associates with the distal part of the 
β2AR  C-tail  is  NSF  (N-ethylmaleimide-Sensitive  Factor) 
[36]. Despite lacking PDZ domains, NSF also recognizes the 
extreme  C-terminal  sequence  D-S-L-L  and  its  association 
with the receptor is increased upon agonist treatment. NSF 
binding  to  the  β2AR  was  shown  to  be  required  for  both 
receptor  internalization  and  recycling,  but  it  is  unclear 
whether a competition between NSF and NHERF binding to 
the receptor takes place and how this process is regulated. 
  The role of the PDZ binding sequence in the β2AR was 
validated  in  cardiac  myocytes  by  the  same  group  which 
investigated  the β1AR-mediated  effects on  contraction rate 
[37].  Deletion  of  the  PDZ  binding  motif  in  the  β2AR 
abolished its coupling to Gi resulting in higher contraction 
rate, in contrast to the effect observed for the β1AR, where a 
similar  mutation  promoted  Gi  coupling  and  decreased 
contraction  [24].  In  agreement  with  previous  findings,  the 
mutated β2AR lacking interaction with NHERF was unable 
to recycle back to the plasma membrane. The experimental 
design  did  not  allow  to  discriminate  between  NSF-  and 
NHERF1-mediated effects.  
  Stimulation of the β2AR raises intracellular cAMP levels 
leading  to  activation  of  protein  kinase-A  (PKA).  The 
functional connection between the β2AR and PKA prompted 
the  investigation  on  potential  interactions  between  this 
receptor and PKA-anchoring proteins, or AKAPs. The first 
AKAP found to bind the β2AR was AKAP250, also known 
as  gravin.  Association  of  gravin  to  the  receptor  was 
increased upon agonist treatment [38] and involved the C-
terminal portion of the receptor [39]. Suppression of gravin 
expression  using  an  antisense  strategy  disrupted  receptor 
resensitization  and  impaired  its  association  to  GRK2, 
βarrestin and clathrin, suggesting that gravin might serve as 
a  scaffold  bringing  together  kinases,  phosphatases  and 
proteins of the endocytic machinery.  
  Another  AKAP,  AKAP79,  directly  and  constitutively 
interacts with the β2AR and promotes its phosphorylation by 
PKA,  which  is  obligatory  for  MAPK  activation  by  the 
receptor  [40].  The  anchored  PKA  was  further  shown  to 
phosphorylate  GRK2  enabling  its  translocation  to  the 
membrane  and  subsequent  phosphorylation  of  the  β2AR 
[41].  Thus,  AKAP79  is  involved  in  the  process  of  β2AR 
desensitization  and  internalization  through  the  clathrin-
dependent  pathway.  The  molecular  determinants  of  the 
receptor  interaction  with  AKAPs  were  unfortunately  not 
finely  mapped  and  the  question  of  the  specificity  of  this 
interaction among adrenergic receptor subtypes has not been 
addressed yet. 
  An interaction of the β2AR with the adaptor protein Grb2 
has  also  been  reported  [42].  This  interaction  was  not 
identified through unbiased screening, but specifically tested 
based  on  the  observation  that  insulin  abolishes  catechol-
amine response by stimulating tyrosine phosphorylation of 
the β2AR. This phosphorylation creates an SH2 site on the 
β2AR  which  induces  Grb2  binding  to  the  receptor  at 
Tyr250/254 thus leading to receptor-G protein uncoupling. 
Grb2 binding to the receptor was increased upon cell treat-
ment with insulin and promoted also receptor internalization 
[43]. 
  Interesting  interactions  have  been  found  between  the 
β2AR and ion channels involved in the regulation of mem-
brane excitability. The β2AR was found to directly interact 
with  the  voltage-gated  calcium  channel  Cav1.2  in  hippo-
campal neurons [44]. A complex containing the β2AR, the 
Cav1.2, G protein, an adenylate cyclase, PKA and the PP2A 
phosphatase  might  represent  a  mechanism  ensuring  a 
specific and highly localized signaling process.  
  It  is  well  known  that  β2AR  and  PKA  activation  can 
increase BKCa activity in neurons, smooth muscle cells and 
other excitable cells. Recent findings indicate that the β2AR 
can interact with calcium sensitive K
+ channels (BKCa) in a 
complex containing the receptor, BKCa and AKAP79 [45]. 
Thus, the β2AR might interact with both the Cav1.2 calcium 
channel  and  the  BKCa  calcium  sensitive  K
+  channel,  and 
these interactions might enable a highly localized control of 
membrane excitability. 
  A recent study reports a fascinating finding concerning 
the interaction between the β2AR and two proteins, the von 
Hippel-Lindau tumor  suppressor protein (pVHL)-E3 ligase 
complex and the dioxygenase EGLN3 [46]. It is known that 
in  response  to  hypoxia  there  is  a  decreased  expression  of 
β1AR  in  heart  attributed  to  high  levels  of  catecholamines 
whereas the β2AR abundance increases suggesting a direct 
regulation of this receptor by oxygen. The metallo-sensory 
enzyme  dioxygenase  EGLN3  transduces  O2-responsive 
signals  through  modifications  of  target  proteins.  Thus,  the 
interaction of EGLN3 with the β2AR results in hydroxylation 
of Pro382 and Pro395 of the receptor. After hydroxylation of 
the β2AR, pVHL-E3 ligase is recruited triggering ubiquitiny-
lation  of  the  β2AR  and  its  degradation.  This  finding 
highlights the broadness and  complexity of protein-protein 
interactions  that  can  be  explored  to  understand  receptor 
function and regulation. 
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PROTEINS INTERACTING AT THE β3AR 
  The  β3AR  subtype  was  cloned  several  years  after  the 
other  βAR  subtypes  and  its  distribution  seems  to  be  res-
tricted to adipose tissue, skeletal and smooth muscles. For 
these  reasons  little  is  known  to  date  about  the  specific 
interactions of this AR subtype. One cytoplasmic partner has 
been identified, namely the tyrosine kinase Src, that can bind 
through its SH3 domain to the polyproline region in the third 
intracellular  loop  and  the  C-tail  of  the  receptor  [13].  The 
direct binding of Src of the β3AR seems required for ERK1/2 
activation by the receptor. Previous reports from the same 
group  had  demonstrated  an  involvement  of  Src  in  MAPK 
activation by the β2AR, but this effect was mediated by the 
interaction of Src with βarrestin. As mentioned above, direct 
Src binding to the β3AR occurred through its SH2 domain on 
the phosphotyrosine Tyr350. The paucity of data regarding 
β3AR interactions leaves open an entire field of investigation 
in the signaling of this receptor. 
PROTEINS INTERACTING AT THE α1AAR 
  Few interactions have been shown to occur selectively at 
the α1aAR subtype. Yet, this receptor contains a PDZ bind-
ing sequence G-E-E-V at its C-terminus that can be expected 
to give rise to PDZ-domain mediated interactions. An early 
report, at the issue of a yeast two-hybrid screen, identified 
the  type  III  PDZ  domain  of  nNOS  (neuronal  nitric  oxide 
synthase)  as  a  potential  α1aAR  interacting  protein  [47]. 
However, co-immunoprecipitation studies, while confirming 
this interaction, failed to highlight selectivity for the α1aAR 
subtype  since  all  three  α1AR  subtypes  could  be  co-
immunoprecipitated  with  nNOS  and  this  even  when  they 
were lacking their C-terminus. This interaction appeared to 
be without apparent physiological implications in spite of the 
known role of NO in the regulation of blood pressure and of 
nNOS  as  local  metabolic  inhibitor  of  α1AR-mediated 
vasoconstriction.  
  Another study reported that mammalian tolloid (mTLD) 
could interact with  the α1aAR [48]. The  CUB5 domain of 
mTLD, a  zinc-finger matrix metalloprotease of the  astacin 
family, interacted with α1aAR C-tail in a yeast two hybrid 
screen. The interaction was specific for the α1aAR and the 
binding region on the receptor could be narrowed down to a 
sequence  of  37  aminoacids.  Overexpression  of  mTLD 
reduced the number of cell surface receptors without affect-
ing total receptor level or affinity when transiently expressed 
in HEK293 cells. mTLD also appeared to facilitate calcium 
signalling  evoked  by  phenylephrine.  No  mechanism  was 
proposed to account for the observed phenomena. 
  Interesting  prospects  were  opened  by  the  report  of  the 
direct  interaction  between  RGS2  (Regulator  of  G  protein 
Signaling  2)  and  the  third  intracellular  loop  of  the  α1aAR 
[49].  RGS  proteins  are  well  characterized  inhibitors  of 
heterotrimeric G protein function, acting as GAPs (GTPase 
activating proteins) to increase the rate of GTP hydrolysis at 
Gα subunits and thus terminate signaling. More than 30 RGS 
proteins have been identified so far, but many RGS proteins 
can non-selectively bind to and inhibit Gαi/o and Gαq11 in 
reconstituted  systems,  suggesting  that  other  factors  may 
regulate their specificity for a particular signaling pathway. 
RGS2  was  found  to  interact  with  the  α1aAR  third  intra-
cellular  loop  confirming  what  previously  shown  for  other 
Gq-coupled  receptors,  namely  the  cholinergic  muscarinic 
M1,  M3  and  M5  receptors  [50]  and  it  inhibited  agonist-
induced  inositol  phosphate  responses  without  affecting 
ligand binding. 
PROTEINS INTERACTING AT THE α1BAR  
  Two main interacting partners were pulled out of a yeast 
two-hybrid screen for the α1bAR: the µ2 (or AP50) subunit 
of the clathrin adaptor complex AP2 [51] and ezrin, a mem-
ber of the ERM protein family [52]. The AP2 complex is 
part of the endocytic machinery mediating clathrin-depend-
ent endocytosis of membrane proteins and it is recruited to 
agonist-activated  GPCRs  through  the  intermission  of 
βarrestins. Interactions of the AP50 subunit are dependent 
upon a YxxF motif present in the cargo protein. However, in 
the case of  the α1bAR, binding of AP50 relied on a basic 
stretch of eight arginines in the proximal C-tail of the recap-
tor. Direct association of the α1bAR to AP50 contributed to 
the  agonist-induced  internalization  of  the  receptor  as 
demonstrated by the fact that a receptor mutant lacking the 
AP50  binding  motif  was  delayed  in  internalization.  The 
presence of the eight arginine motif in the C-tail of a GPCR 
is not common, which rules out the hypothesis  that direct 
AP50  interaction  is  a  common  mechanism  for  clathrin-
mediated endocytosis. Interestingly, this feature is shared by 
the  α1dAR,  which  contains  a  stretch  of  seven  positive 
charges in its C-tail, but no studies were undertaken using 
this receptor subytpe. 
  In addition to AP50,  the same yeast two-hybrid screen 
identified ezrin as a potentially direct binding partner of the 
α1bAR [52]. Ezrin belongs to the ERM family of proteins, 
primarily  described  as  linkers  between  membrane  proteins 
and cortical actin. Ezrin was also shown to be involved in the 
remodelling of the actin cytoskeleton, in the modulation of 
Rho signaling (by binding to Rho GTP dissociation inhibitor 
(GDI)  and  through  direct  association  to  several  Rho 
GTP/GDP exchange factors (GEFs) as well as in anchoring 
of  PKA.  Ezrin  interactions  with  polytopic  membrane 
proteins generally occur through the adaptor proteins EBP50 
(NHERF1)  and  E3KARP  (NHERF2),  but  direct  contacts 
were also described between ezrin and proteins such as the 
Na+/H+ exchanger type 1 (NHE1) and podocalyxin. So far, 
a  role  for  the  ERM  proteins  in  GPCR  trafficking  was 
inferred  from  the  finding  that  NHERF1  binding  to  some 
GPCRs promoted their recycling, depending on its binding 
to ERM proteins. The α1bAR is the first GPCR for which a 
direct interaction with ezrin has been found. Disruption of 
this  interaction  by  overexpression  of  a  dominant  negative 
mutant of ezrin inhibited receptor recycling after internaliza-
tion, as did actin depolymerization. Thus, the involvement of 
ERM proteins in GPCR recycling, through either a direct or 
indirect  interaction  with  the  receptor,  might  represent  a 
general paradigm for the regulation of GPCR trafficking.  
  Intriguingly, ezrin and AP50 shared the same binding site 
on the α1bAR C-tail, consisting in the eight arginines stretch 
positioned after the putative palmitoylation site. In pulldown 
experiments the binding domain of ezrin and that of AP50 
competes with each other for the same binding site of the 
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regulated  within  the  cell  is  a  matter  that  awaits  further 
inquiry. 
  Another protein, the receptor for globular "Heads" of c1q 
(gC1qR),  was reported to  interact with the same arginine-
rich sequence  in  the α1b and  the α1dAR [53]. gC1qR  is  a 
glycoprotein mainly displaying intracellular localization, but 
also  present  on  the  surface  of  macrophages  and  T  cells 
through anchoring to β-integrin, where it is part of a com-
plement receptor. No functional relevance was demonstrated 
for its interaction with the α1b or α1dAR. 
PROTEINS INTERACTING AT THE α1DAR 
  The α1dAR was for a long time a “poor relative” to the 
other α1AR subtypes, the α1a and α1b because poorly exp-
ressed at the cell surface in heterologous systems, probably 
because of  its long N-terminus.  This peculiarity hampered 
the  investigation  of  its  potential  interactions  with  other 
proteins. Apart from  the above  mentioned  interaction with 
gC1qR,  whose  functional  implications  are  unknown  [53], 
another interacting partner of the α1dAR was α-syntrophin 
[54].  α-syntrophin,  a  protein  containing  one  PDZ  domain 
and  two  PH  (pleckstrin  homology)  domains,  specifically 
recognized the C-tail of the α1dAR, but not that of the α1a or 
α1b,  in  the  yeast  two-hybrid  assay.  The  PDZ  domains  of 
syntrophin isoforms α, β1 and β2, but not γ1 or γ2, could 
interact with the α1dAR C-tail. The α1dAR possesses the C-
terminal  sequence  E-T-D-I,  whose  mutation  impaired 
syntrophin binding to the receptor and markedly decreased 
norepinephrine-induced  inositol  phosphate  accumulation. 
This mutation also dramatically decreased receptor expres-
sion  levels.  Interestingly,  syntrophins  seemed  to  interact 
equally well with  intracellular or surface-expressed α1dAR 
receptors.  Taken  altogether  these  results  suggested  that 
syntrophins  act  to  maintain  the  stability  of  the  α1dAR 
through a PDZ-mediated interaction. 
PROTEINS  INTERACTING  AT  THE  α2AR  SUB-
TYPES 
  The three α2AR receptor subtypes (α2A α2B  and α2C) 
are coupled to the Gi/o family of heterotrimeric G proteins, 
and hence to the inhibition of adenylyl cyclase and voltage 
sensitive  calcium  channels, and  to the activation of potas-
sium  channels.  They  are  differently  expressed  in  various 
tissues including the basolateral membrane of polarized renal 
epithelial  cells  where  differences  in  the  targeting  and 
trafficking of the three subtypes have been found. The proper 
basolateral  retention  of  the  α2AR  receptor  subtypes  is 
dependent upon the integrity of their third intracellular loop, 
a finding which prompted the search for partners interacting 
with this region of the receptors. A gel overlay strategy using 
in vitro translated i3 loops of the α2AR receptors highlighted 
the interaction of the zeta isoform of 14-3-3-proteins [55]. 
14-3-3 proteins are ubiquitous and involved in the regulation 
of a number of signaling pathways, among which the Ras/ 
MAPK cascade. 14-3-3 interacted preferentially with the α2A 
and α2B than with the α2C. A detailed study of the sequence 
requirements  for  this  interaction  at  the  α2AAR  did  not 
identify  a  single  linear  motif  suggesting  that  a  three 
dimensional  structure  in  the  i3  loop  is  needed  for  14-3-3 
binding [56]. 
  An important binding partner of all three α2AR subtypes 
is  spinophilin  [57,  58].  This  interaction  was  specifically 
tested with the rationale that spinophilin is enriched beneath 
the  basolateral  membrane  of  MDCK  cells.  Spinophilin 
binding to α2AAR was enhanced by agonist treatment and the 
region responsible for binding was loosely mapped to the N- 
and  C-terminal  ends  of  the  i3  loop  [56].  Interaction  with 
spinophilin contributed to the cell surface stabilization of the 
α2BAR subtype, a receptor that displays the unique property 
of  being  first  randomly  delivered  to  both  apical  and 
basolateral side of the cell, with a much faster apical versus 
basolateral turnover which ends up in its accumulation on the 
basolateral side. Apical delivery of a spinophilin subdomain 
extended the half-life of the α2BAR in this region; further-
more, agonist-stimulated internalization of the receptor was 
accelerated in fibroblats derived from spinophilin knock-out 
mice  [59].  Presumably,  similar  effects  could  occur  at  the 
other two α2AR subtypes. An explanation of this effect came 
from the finding that spinophilin blocks GRK2 association to 
the α2BARs thus inhibiting receptor endocytosis [60].  
  Spinophilin was also found to interact with other GPCRs, 
including the α1bAR, as well as with the N-terminal domain 
of RGS proteins (RGS1, 2, 4 and 16) which participates in 
GPCR  recognition  [60,  61].  Thus  spinophilin  might 
represent an interesting functional bridge between RGS and 
α1AR subtypes that don't bind RGS, like the α1bAR. In fact, 
it  has  been  found  that  spinophilin  increases  the  RGS2-
induced inhibition of the α1bAR calcium response. In support 
of this finding, a constitutively active α1bAR mutant did not 
bind  spinophilin  and  was  resistant  to  inhibition  by  RGS2. 
Similar resistance to RGS2 inhibition was found to occur in 
spinophilin knock-out cells. These data offer a glimpse into a 
potentially  more  general  regulatory  mechanisms  of  GPCR 
function by spinophilin. 
  The most recent protein found to interact with α2ARs is 
ubiquitin  carboxyl-terminal  hydrolase-L1  (Uch-L1),  a 
protein associated with Parkinson disease [62]. Uch-L1 binds 
preferentially to the α2AAR subtype and its overexpression 
inhibits  the  receptor-induced  activation  of  MAPK.  This 
interaction  might  have  implications  in  the  neuroprotective 
effect of α2ARs which needs to be further investigated. 
OLIGOMERIZATION  OF  THE  ADRENERGIC 
RECEPTORS 
  Findings  in the last decade challenged  the widely held 
view of GPCRs functioning as monomeric units [7]. Early 
biochemical studies showing higher molecular weight recap-
tor bands migrating in SDS-PAGE gels, stabilized by cross-
linking,  suggested  that  adrenergic  receptors  might  form 
oligomers. Afterwards, co-immunoprecipitation of differen-
tially tagged GPCRs or functional complementation of pairs 
of co-expressed inactive receptor mutants provided stronger 
evidence in favor of GPCR oligomers. The widespread use 
of biophysical techniques such as FRET or BRET between 
GPCRs  carrying  the  appropriate  pair  of  fluorescent/ 
bioluminescent labels suggested oligomerization of a variety 
of GPCRs. Each technique employed has its own shortcom-
ings: whereas co-immunoprecipitation cannot rule out indi-
rect interactions, energy transfer techniques can only certify 
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in immediate contact. Therefore, whether receptor oligomeri-
zation involves direct interactions among receptor monomers 
versus their increased proximity in micro-domains of the cell 
membrane  cannot  be  unequivocally  demonstrated.  Despite 
the  fact  that  the  precise  molecular  events  are  not  fully 
understood,  the  term  of  GPCR  oligomerization  is  largely 
accepted to indicate the existence within the cell membrane 
of  macromolecular  complexes  formed  by  two  or  more 
receptor  monomers.  It  is  important  to  highlight  that  most 
studies have been performed in recombinant cells overexp-
ressing the receptors with very few examples of oligomeriza-
tion occurring in physiological systems. 
Homo-Oligomerization 
  Within the adrenergic receptor family, the β2AR was the 
first member for which homo-oligomerization was described, 
using  co-immunoprecipitation  of  epitope-tagged  receptors 
[63]. BRET technology was then adapted for the purpose of 
showing the existence of receptor oligomers at the cell sur-
face and of quantitatively assessing the extent of oligomeri-
zation  [63,  64].  Homo-oligomerization  was  therefore 
demonstrated for the β2AR [63, 64], β1AR [65], α1a and α1b 
[66, 67], α1d [67], α2a and α2c [68], and for the α2b [69] AR 
subtypes. 
  Whereas the stoichiometry of these complexes is hard to 
assess with either biochemical or biophysical methods used 
so far, the structural architecture of receptor oligomers has 
been addressed by some studies using computational, phar-
macological  and  biochemical  approaches.  Two  types  of 
receptor-receptor interaction have been proposed, involving 
either  lateral  contact  or  domain  swapping.  A  model  was 
proposed for a β2AR dimer where the two receptor mono-
mers swapped helices V and VI [70]. Other studies pointed 
at  helices  I  and  VII  [66]  or  I/II  and  III/IV  [71]  as  the 
probable interface for receptor-receptor contact in the case of 
the α1b AR. Neither the C-terminal tail of the α1bAR nor its 
glycosylation state or the presence or absence of a glycol-
phorin  dimerization  motif  GxxxG  in  the  transmembrane 
domains  affected  its  oligomerization  [66].  This  was  in 
contrast with the previous report of Hébert et al., showing 
that  helix  VI  containing  the  GxxxGxxxG  motif  was 
responsible for oligomerization of the β2AR [63]. 
  The functional implications of AR homo-ligomerization 
have been explored by several studies. Preventing receptor 
association  has  been  technically  difficult  with  few  excep-
tions. In the case of the β2AR, a peptide derived from helix 
VI  was  shown  to  disrupt  dimerization  and  its  use  was 
demonstrated  to  impair  isoproterenol-stimulated  cAMP 
production  by  the  β2  AR  [63]  implying  that  β2  oligomers 
would be the functional form of the receptor. 
  Among  the  functional  implications  of  AR  homo-
oligomers,  different  studies  investigated  their  localization 
within the cell. BRET studies suggested that β2AR oligomers 
are present at the plasma membrane [64]. Biotinylation with 
a membrane-impermeable showed expression of α1a, α1b and 
α1d homodimers at  the cell surface [67]. Moreover, homo-
oligomerization of the β2AR seems to be a prerequisite for 
its  plasma  membrane  targeting  [72].  In  fact,  the  peptide 
derived from helix VI of the β2AR, which blocks receptor 
oligomerization, prevented normal targeting of the receptor 
to the plasma membrane. These results imply that receptor 
oligomers form as early as the stage of their synthesis in the 
endoplsmic  reticulum  and  that  oligomerization  influences 
their maturation and trafficking ability from then onwards. 
Indeed,  co-expression  with  a  recycling-defective  mutant 
diverted  wild  type  β2AR  from  normal  recycling  to  the 
plasma  membrane  to  the  proteolytic  degradative  pathway 
[73].  Similar  data  were  obtained  for  the  α2BAR  subtype; 
when  co-expressed  with  a  mutant  deficient  in  cell  surface 
targeting,  the  wild  type  α2BAR  remained  trapped  in  the 
endoplsmic reticulum [69]. 
  A  matter  of  debate  has  been  the  regulation  of  the 
oligomeric status of GPCRs by ligands. One among the first 
reports  indicated  that  agonist  binding  could  increase  the 
amount of β2AR dimers [63], corroborated by  BRET data 
[64]. In contrast, agonist treatment had no apparent effect on 
the oligomerization of α1AR subtypes [66, 67]. Furthermore, 
constitutively  active  or  non-functional  α1bAR  mutants 
displayed  the  same  propensity  to  oligomerize  as  the  wild 
type receptor [66], indicating that the activation state of the 
receptor is irrelevant for this process. 
Hetero-Oligomerization 
  Different AR subtypes are often co-expressed in the same 
cells and cross-talk among them can occur. Various studies 
addressed  the  hypothesis  that  hetero-oligomerization  could 
account  for  cross-talk  effects.  A  number  of  interactions 
between different  AR  subtypes or between ARs  and more 
distantly related GPCRs have been reported (Table 2).  
  The  adrenergic  receptor  subtypes  seem  to  display 
selectivity of interaction and hetero-oligomers do not form 
for any two receptor combination. Within the AR family, the 
following  main  hetero-oligomers  have  been  found:  β1/β2 
[74], β2/β3 [75], α1b/α1a and α1b/α1d, (but not α1a/α1d) [66, 67, 
76], α1b/β2 [66], α1d/β2 [77], α2A/α2C [68], α2A/β1 [78] and 
α2C/β2 [79].  
  In addition, the following main combinations have been 
described  between  AR  subtypes  and  other  GPCRs:  β2AR/ 
olfactory receptor [80], β2AR/δ opioid and β2AR/κ opioid 
[81], βAR/AT1 angiotensin II [82], β2AR/5-HT4 serotonin 
[83], β2AR/EP1 prostaglandin [84], β2AR/CB1 cannabinoid 
[85], α2A/µ opioid [86] and α2A/δ opioid [87]. Very recently 
a macromolecular complex  including  the β2AR, Gs, PKA, 
adenylate  cyclase  and  the  AMPA  glutamate  receptor, 
mGluR1, has been described [88]. 
  Hetero-oligomerization  was  found  to  have  various 
functional effects upon the behavior of individual receptors, 
ranging  from  regulated  targeting  to  modified  pharmacolo-
gical, signaling or trafficking profile in recombinant systems. 
Co-expression  of  the  α1dAR  with  the  α1bAR  [76]  or  the 
β2AR  [77]  was  able  to  rescue  surface  expression  of  the 
α1dAR, the majority of which is intracellular when expressed 
alone  in  various  cell  lines.  A  similar  phenomenon  was 
already  observed  for  the  GABA-B  receptor  and  for  the 
calcitonin/adrenomedullin  receptor,  both  receptors  needing 
hetero-dimerization in order  to be properly  targeted to  the 
plasma  membrane.  Interestingly,  the  interaction  with  the 
α1bAR modified the pharmacological profile of the α1dAR 
which looses its affinity for its selective ligand BMY7378 
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behaves as a single functional entity with increased response 
to  norepinephrine  relative  to  either  monomer  alone.  The 
α1dAR receptor was long supposed to be little expressed in 
the heart, as its selective ligand BMY7378 could detect only 
minimal  levels  of  the  receptor.  However,  these  findings 
should be considered in a new light, given that the α1b and 
α1dAR  subtypes  co-exist  in  this  tissue  and  the  pharma-
cological  profile  of  the  α1dAR  might  be  different  than 
expected because of oligomerization.  
  Hetero-dimerization of the β2AR with the α2CAR, which 
is normally poorly expressed in recombinant cells, increased 
the expression at the cell surface and ERK1/2 signaling of 
the α2CAR [79]. Coexpression of the α2CAR with more than 
twenty-five GPCRs revealed that only the β2AR induced this 
effect. Coexpression of the β2AR with the olfactory receptor 
(M71)  also  promoted  the  cell  surface  localization  of  this 
receptor  which  is  often  co-expressed  with  the  β2AR  in 
olfactory neurons [80]. Again, only the β2AR among the AR 
subtypes had this effect.  
  Beyond its effect on receptor targeting to the cell surface, 
hetero-oligomerization seems to have an impact on various 
aspects of receptor trafficking and signaling. For example, 
several  studies  have  shown  that  receptor  monomers  can 
mutually  influence  their  endocytosis  pattern.  Whereas  the 
α1bAR undergoes agonist-induced internalization, the α1aAR 
does  not.  However,  when  the  two  AR  subtypes  were  co-
expressed  forming  heterodimers,  the  endocytosis  of  each 
monomer could be triggered by stimulation of the other [66]. 
Colocalization  of  the  two  monomers  could  be  seen  in 
endocytic  vesicles  suggesting  that  the  α1a/α1b  dimers 
remained stable throughout the endocytosis process.  
  Strikingly,  in  β1/β2  heterodimers,  the  internalization  of 
the  β2AR  within  the  complex  was  inhibited.  Furthermore, 
β2AR-induced ERK activation was equally blocked by co-
expression of β1AR [78]. Similar results were also found for 
the β2/β3 heterodimer [79] in which β2AR internalization was 
impaired.  The  β3AR  is  resistant  to  agonist-promoted 
endocytosis and, like the β1AR, acted as a dominant negative 
on β2AR internalization. 
  In  α2A/β1  heterodimers,  stimulation  of  the  α2AAR  trig-
gered the internalization of the β1AR [78]. In addition, the 
β1AR  within  the  heterodimer  displayed  altered  pharmaco-
logy. In α2A/α2C heterodimers, the GRK-dependent phospho-
rylation  and  βarrestin  recruitment  at  the  α2AAR,  were 
inhibited [68]. 
  Functional  cross-talk  was  also  described  between  the 
β2AR  and  the  opioid  receptors  (OR)  that  are  coupled  to 
stimulatory and inhibitory G proteins, respectively. Whereas 
in the β2/δ opioid dimer the β2AR and δOR could facilitate 
the endocytosis of each other, in the β2/κ opioid dimer the 
internalization  of  the  β2AR  was  inhibited.  Moreover, 
isoproterenol-induced  MAPK activation was diminished in 
presence of κOR, showing that the κOR acts as a dominant 
negative modulator of the β2AR [81].  
  The  same  group  explored  the  possible  interaction 
between  α2AR  and  opioid  receptors  that  colocalize  in 
neurons  and  affect  the  nociceptive  response.  The  α2A/µ 
opioid could be isolated from recombinant cells as well as 
from  primary  neurons.  In  the  α2A/µ  opioid  dimer  the 
activation of each monomer increases G protein and MAPK 
signaling whereas the activation of both monomers decreases 
it [86]. In addition, when the receptors were expressed in a 
neuronal  cell  line  the  α2AAR  increased  the  δOR-mediated 
neurite outgrowth [87]. These results support the notion that 
α2AR and opioid receptors are synergic in spinal analgesia 
as also demonstrated by the decrease in morphine-induced 
analgesia  in  α2A-/-  knock  out  mice.  Thus,  the  physical 
association  between  the  α2AR  and  opioid  receptors  might 
explain their functional interaction.  
  Some interesting findings have been reported concerning 
the  potential  implications  of  βAR  hetero-oligomerization 
with other GPCRs in native tissues. Whether in native tissues 
simultaneous synthesis of hetero-dimer partners can occur or 
different  receptors  are  simply  clustered  in  the  same  cell 
membrane compartment is not known. 
  In  freshly  isolated  mouse  cardiomyocytes,  interesting 
effects were reported on contractility induced by angiotensin 
II (AgII) acting at AT1 receptor or isoproterenol acting at 
βAR  [82].  Whereas  the  beta-blocker  propranolol  could 
inhibit the effect of AgII, the AT1 blocker valsartan inhibited 
that of isoproterenol. This transinhibitory effect of the two 
antagonists seemed related to inhibition of receptor coupling 
to its cognate G protein. Biochemical experiments on β2AR 
and AT1 receptor expressed in HEK cells indicated that the 
two  receptors  could  be  co-immunoprecipitated  thus  sug-
gesting  that  hetero-oligomerization  of  the  two  receptors 
could be the basis of their functional interaction in heart. 
  Hetero-oligomerization  between  the  β2AR  (coupled  to 
Gs) and the EP1 prostaglandin receptor (coupled to Gq) has 
been  observed  in  airway  smooth  muscle  [84].  In  mouse 
tracheal  rings,  activation  of  the  β2AR  induces  muscle 
relaxation whereas stimulation of EP1 alone has no effect on 
contraction.  However,  stimulation  of  the  EP1  receptor 
profoundly reduced the β2AR-induced muscle relaxation and 
cAMP accumulation. The modulatory effect of EP1 receptor 
on the β2AR might depend on the interaction between the 
two  receptors  which  form  heterodimers  in  airway  smooth 
muscle cells. 
  Hetero-oligomerization has also been recently observed 
using  BRET  between  the  β2AR  and  the  CB1  cannabinoid 
receptor expressed in recombinant cells [85]. The formation 
of oligomers could be increased by a CB1 inverse agonist. 
Interestingly, co-expression of the two receptors resulted in 
increased  localization  at  the  cell  surface  and  decreased 
constitutive activity of the CB1 receptor. Complex functional 
interactions  on  signaling  between  the  two  receptors  have 
been found both in the recombinant system and in primary 
human  trabecular  meshwork  (HTM)  cells  from  the  eye,  a 
tissue in which the two receptors are natively co-expressed. 
Beyond mutual effects on ERK activation, activation of one 
receptor  induces  cross-desensitization  of  the  other  both  in 
recombinant and HTM cells. This might be relevant in drug 
therapy since CB1 agonists and β2AR antagonists can both 
reduce intraocular pressure.  
  Very  recently,  an  elegant  study  demonstrated  that  the 
β2AR can form a signaling complex with the GluR1 subunit 
of the AMPA glutamate receptor including also the trimeric 
Gs protein, adenylate cyclase and protein kinase A [88]. This 
complex  seems  to  be  important  to  allow  β2AR-induced Protein-Protein Interactions at the Adrenergic Receptors  Current Drug Targets, 2012, Vol. 13, No. 1     23 
phosphorylation  of  the  GluR1  which  results  in  increased 
GluR1 cell surface expression and current amplitudes. 
CONCLUSIONS AND PERSPECTIVES 
  The  AR  subtypes  have  been  found  to  interact  with 
several  proteins  (Table  1)  as  well  as  to  form  homo  and 
hetero-oligomers (Table 2). A critical approach in analyzing 
all these interactions should address a number of questions: 
is  the  interaction selective for one receptor or common to 
others?  is  it  occurring  in  specific  tissues?  what  are  its 
functional  implications?  Addressing  these  questions  is 
important to assess whether the interface of a receptor with a 
specific  protein  could  be  an  interesting  target  of  pharma-
cological intervention. For most interactions described at the 
Table 1. Proteins Selectively Interacting with Distinct Adrenergic Receptor Subtypes 
 
Receptor  Partner  Binding Site  Functional Role  Refs. 
β1  endophilins  i3 loop (Pro-rich)   endocytosis  [17] 
β1  PSD-95  C-tail (ESKV)   endocytosis; β1 /NMDA receptor association  [18] 
β1  MAGI-2  C-tail (ESKV)   endocytosis; association to β-catenin  [20] 
β1  GIPC  C-tail (ESKV)   ERK activation  [21] 
β1  CAL  C-tail (ESKV)   cell surface expression  [22] 
β1  CNrasGEF  C-tail (ESKV)  Ras activation  [23] 
β1  MAGI-3  C-tail (ESKV)   ERK activation  [25] 
β1  GASP  C-tail (ESKV)  unknown  [26] 
β1  golgin-160  i3 loop   cell surface expression  [28] 
β1  14-3-3  phospho-sites  regulation of K
+ current  [29] 
β1  PDE4D8  unknown  regulation of cAMP levels  [30] 
β2  NHERF (or EBP50)  C-tail (DSLL)  regulation of NHE3; regulation of PDGF and CFTR activity; receptor recycling  [31] 
β2  NSF  C-tail (DSLL)   endocytosis  [36] 
β2  AKAP250 (gravin)  C-tail   endocytosis and resensitization;  association to GRK2 and βarrestin  [38] 
β2  AKAP79  unknown   agonist-induced phosphorylation by GRK2  [40, 
41] 
β2  Grb2  Tyr350/354   endocytosis stimulated by insulin  [42] 
β2  Cav1.2  unknown   Ca
++ current  [44] 
β2  BKCa  unknown   K
+ current  [45] 
β2  pVHL 
EGLN3 
Pro382/395  O2-induced ubiquitinylation  [46] 
β3  Src  i3 loop and C-tail 
(Pro-rich) 
 ERK activation  [13] 
α1a α1b α1d  nNOS  unknown  unknown  [47] 
α1a  tolloid  C-tail   surface expression  [48] 
α1a  RGS2  i3 loop 
(K219-S220-R238) 
 Gq signaling  [49] 
α1b  AP50  C-tail (8 Arg)   endocytosis  [51] 
α1b  ezrin  C-tail (8 Arg)   recycling  [52] 
α1b  spinophilin  i3 loop   Ca
2+ signaling induced by RGS2  [61] 
α1d  syntrophins  C-term (ETDI)  stabilization of receptor at cell surface  [54] 
α1b α1d  gC1qR  C-tail (Arg)  unknown  [53] 
α2A α2B 
α2C 
14-3-3 z  i3 loop  unknown  [55] 
α2A α2B 
α2C 
spinophilin  i3 loop  stabilization of receptor at cell surface;  arrestin action  [55, 
56] 
α2A  Uch-L1  i3 loop   MAPK activation  [62] 
 24    Current Drug Targets, 2012, Vol. 13, No. 1  Cotecchia et al. 
AR  subtypes,  the  answers  to  these  questions  are  far  from 
being answered. 
  Most of the interactions involving the AR subtypes have 
been found using various screening approaches (proteomic, 
yeast  two  hybrid  or  pull-down  experiments)  without  a 
specific  bias  towards  the  interactions  searched.  In  most 
studies,  the  investigation  of  the  interactions  has  been 
performed in recombinant systems in which only a limited 
number of functional parameters common to all GPCRs can 
be explored, i.e. trafficking, signaling through known path-
ways, receptor pharmacology. This resulted in the identifi-
cation of a number of proteins affecting receptor endocytosis 
(endophilins,  PSD-95,  MAGI-2,  NSF,  AKAP250,  Grb2, 
AP50) and few others stabilizing receptor expression at the 
cell  surface  (golgin-160,  spinophilin,  syntrophin),  favoring 
recycling (ezrin, NHERF) or regulating receptor coupling to 
G proteins (RGS2) (Table 1). Most of these interactions have 
been  investigated  only  at  a  specific  AR  subtype  with  few 
exceptions. For example, the role of spinophilin in stabiliz-
ing receptor expression at the cell surface seems a property 
of  all  three  α2AR  subtypes  (α2A,  α2B  and  α2C)  [55,  56]. 
Spinophilin has been found to interact also with the α1bAR 
displaying, however, a different effect, i.e. the modulation of 
calcium signaling. Spinophilin certainly represents a protein 
of  pharmacological  interest  which  should  be  further 
investigated because of its well established role in targeting 
the α2AR subtypes in polarized cells as well as in regulating 
their function.  
  It seems quite evident that proteins containing the PDZ 
domain can interact with both the β1 and β2AR. However, 
some  PDZ  domain  containing  proteins  seem  to  display  a 
selectivity towards either one of two receptors. For example, 
NHERF interacts with the C-tail of the β2AR, but not with 
the β1 [31]. PSD-95 interacts selectively with the β1AR being 
both proteins expressed in post-synaptic densities [18]. The 
interaction of PDZ proteins with the β1 and β2AR is also one 
of the few examples in which the functional implication has 
been  investigated  in  a  physiological  system,  i.e.  mouse 
cardiac  myocytes  [24,  37].  Deletion  of  the  PDZ  binding 
motif in the β2AR abolished its coupling to Gi resulting in 
higher contraction rate, in contrast to the effect observed for 
the β1AR, where a similar mutation promoted Gi coupling 
and  decreased  contraction.  Because  of  the  functional  rele-
vance of these interactions, PDZ domain containing proteins 
might  represent  interesting  targets  to  pharmacologically 
interfere  with  trafficking  and  signaling  of  either  the  β1  or 
β2AR.  Recently,  some  success  has  been  reported  in 
designing small peptides blocking PDZ interactions [89]. In 
addition, despite the wide distribution of PDZ proteins, the 
overlapping  expression  of  interacting  partners  might  be 
restricted  to  some  tissues  and  this  could  be  functionally 
relevant. More detailed studies on this important family of 
proteins in the regulation of AR subtypes are required and 
might have important implications. 
  Beyond  the  various  interacting  proteins  found  using 
different  screening  approaches,  few  highly  interesting  
 
Table 2. Hetero-Oligomerization of the Adrenergic Receptors 
 
Receptors  Trafficking  Pharmacology  Signaling  Refs. 
β1/β2  no β2 endocytosis     β2 ERK activation  [74] 
β2/β3  no β2 endocytosis    no Gi/o coupling  [75] 
β2/Olf   Olf surface expression; co-endocytosis      [80] 
β2/δOR  co-endocytosis      [81] 
β2/kOR  no β2 endocytosis     β2 MAPK activation  [81] 
β2/AT1  trans-inhibition of endocytosis by 
antagonists 
  trans-inhibition of G protein coupling by 
antagonists 
[82] 
β2/5-HT4        [83] 
β2/EP1       β2 smooth muscle relaxation  [84] 
β2/CB1   constitutive endocytosis of CB1; co-
endocytosis 
  mutual effects on signaling; cross-desensitization  [85] 
α1a/α1b  co-endocytosis  no change    [66] 
α1b/α1d   α1d surface expression   α1d affinity for selective 
ligands 
 signaling  [67, 
76] 
α1d/β2   α1d surface expression; co-endocytosis      [77] 
α2A/α2c       α2A phosphorylation & βarrestin recruitment  [68] 
α2A/β1  co-endocytosis  altered β1 profile    [78] 
α2C/β2   α2C surface expression     α2C ERK signaling  [79] 
α2A/µOR       signalling of each monomer  [86] 
α2A/δOR       δOR neurite outgrowth  [87] 
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interactions have been found in elegant studies exploring the 
activity of the β2AR in neuronal cells. The β2AR was found 
to directly interact with the voltage-gated calcium  channel 
Cav1.2 in hippocampal neurons [44]. It was reported that the 
β2AR can also interact with calcium sensitive K
+ channels 
(BKCa)  in  a  complex  containing  the  receptor,  BKCa  and 
AKAP79 [42]. Thus, the β2AR might interact with both the 
Cav1.2 calcium channel and the BKCa calcium sensitive K
+ 
channel, and these interactions might enable a highly loca-
lized control of membrane excitability. Another recent study 
has  reported  that  the  β2AR  can  form  a  signaling  complex 
with  the  GluR1  subunit  of  the  AMPA  glutamate  receptor 
including also the trimeric Gs protein, adenylate cyclase and 
protein kinase A [88]. This complex might underlie the faci-
litating effect of βARs on long term potentiation mediated by 
AMPA receptors. 
  Altogether,  these  latter  studies  clearly  indicate  that  the 
full elucidation of signaling events in  time  and space will 
depend on a much deeper understanding of the interactions 
among receptors and signaling molecules. Developing drugs 
acting at distinct receptor-protein interfaces might represent 
an approach to achieve more cell specific pharmacological 
effects. However, this field is still at an early stage because 
of the complexity of studying these events in physiological 
cell  systems  as  demonstrated  by  the  limited  number  of 
studies published so far. Therefore, the fine-tuning of GPCR 
activity by receptor-interacting proteins is a very promising 
area of investigation in which a lot remains to be explored 
[90]. Studies in recombinant systems can certainly provide 
some useful information, but the real challenge concerns the 
possibility  of  exploring  the  functional  implications  of  a 
variety of interactions in different tissues and physiological 
conditions. Without these studies it will be difficult to assess 
which of these interactions are druggable. 
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